Liquidia Co. (NASDAQ:LQDA) Given Average Rating of “Moderate Buy” by Brokerages

Liquidia Co. (NASDAQ:LQDA) has been given a consensus recommendation of “Moderate Buy” by the ten research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $24.00.

LQDA has been the subject of several analyst reports. Lifesci Capital began coverage on Liquidia in a research note on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price target for the company. HC Wainwright restated a “buy” rating and set a $29.00 price objective on shares of Liquidia in a research report on Thursday, November 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 target price on shares of Liquidia in a report on Thursday, November 14th. Raymond James raised shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a report on Monday, August 19th. Finally, Scotiabank started coverage on Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price objective on the stock.

Insider Activity at Liquidia

In related news, CEO Roger Jeffs sold 8,053 shares of the stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $89,468.83. Following the sale, the chief executive officer now directly owns 812,193 shares of the company’s stock, valued at approximately $9,023,464.23. This represents a 0.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Rajeev Saggar sold 2,260 shares of Liquidia stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $25,108.60. Following the transaction, the insider now owns 207,383 shares of the company’s stock, valued at approximately $2,304,025.13. The trade was a 1.08 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,551 shares of company stock valued at $236,021 in the last ninety days. Corporate insiders own 30.10% of the company’s stock.

Institutional Trading of Liquidia

Large investors have recently modified their holdings of the business. Swiss National Bank purchased a new stake in Liquidia in the 1st quarter valued at approximately $1,325,000. Sei Investments Co. acquired a new stake in shares of Liquidia during the first quarter valued at $531,000. Vanguard Group Inc. increased its position in Liquidia by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock worth $42,587,000 after purchasing an additional 43,352 shares in the last quarter. American International Group Inc. raised its stake in Liquidia by 5.2% in the 1st quarter. American International Group Inc. now owns 24,806 shares of the company’s stock valued at $366,000 after purchasing an additional 1,215 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Liquidia in the 1st quarter valued at about $1,755,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Liquidia Stock Up 1.7 %

Shares of LQDA stock opened at $11.61 on Friday. The stock’s 50-day moving average price is $10.70 and its 200 day moving average price is $11.37. The stock has a market capitalization of $982.64 million, a PE ratio of -7.12 and a beta of 0.21. Liquidia has a 52-week low of $6.82 and a 52-week high of $16.99.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).